US FDA identifies cases of liver injury after treatment with Intercept's drug
Adds details in paragraphs 3-4, background in paragraphs 5-6
Dec 12 (Reuters) -Intercept Pharmaceuticals' liver disease drug is being observed for injury to the organ in patients without severe scarring, the U.S. Food and Drug Administration said on Thursday, based on its review of post-market clinical trial data.
The regulator had restricted the use of the drug, Ocaliva, in patients with advanced cirrhosis or scarring of the liver in 2021.
The FDA said on Thursday it has identified cases of serious liver injury among patients being treated for primary biliary cholangitis, a rare disease that causes inflammation of small bile ducts in the liver and can eventually destroy them.
Discontinue Ocaliva treatment with any evidence of liver disease progression or if efficacy is not established, the regulator recommended health care professionals.
This is another setback to the company after the regulator did not convert its accelerated nod for Ocaliva into a full approval last month.
Under the accelerated pathway, the FDA mandates additional post-market trials that verify the drug's benefits. If data from the trials do not show the drug's effectiveness, the regulator could ask the company to withdraw it from the market.
Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
